secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2026-08-11T11:00:31+00:00
Accession:  0001171843-26-005405
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q2 revenue up 11% to $22.7M; raises FY2026 revenue guidance to 3-5%
--------------------------------------------------------------------------------

- Q2 2026 revenue $22.7M, up 11% YoY from $20.5M; FX tailwind of ~1% on constant-currency basis
- Net loss widened to ($2.9)M from ($2.3)M; adjusted EBITDA up to $1.7M from $1.5M
- H1 net loss narrowed to ($6.3)M from ($52.6)M, which included $48.0M Q1 2025 goodwill impairment
- Raises FY 2026 revenue guidance to 3%-5% YoY growth; maintains adjusted EBITDA target
- Growth driven by telemetry and CMT products (AAA, electroporation) plus China demand; H1 operating cash flow ($0.3)M vs $5.7M

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184326005405/0001171843-26-005405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184326005405/f8k_081126.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer